推荐产品
化驗
≥98% (HPLC)
形狀
powder
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear
儲存溫度
−20°C
生化／生理作用
JH-II-127 is an orally available, brain penetrant, potent and selective inhibitor of both wild-type and G2019S mutant Leucine-rich repeat kinase 2 (LRRK2). JH-II-127 inhibits phosphorylation of the Ser910 and Ser935 of both wild-type and G2019S mutant LRRK2. It causes complete inhibition of LRRK2 in mouse brain at 100 mg/kg.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Farzaneh Atashrazm et al.
Clinical pharmacology : advances and applications, 8, 177-189 (2016-11-02)
Major advances in understanding how genetics underlies Parkinson's disease (PD) have provided new opportunities for understanding disease pathogenesis and potential new targets for therapeutic intervention. One such target is leucine-rich repeat kinase 2 (LRRK2), an enigmatic enzyme implicated in both
John M Hatcher et al.
ACS medicinal chemistry letters, 6(5), 584-589 (2015-05-26)
Activating mutations in leucine-rich repeat kinase 2 (LRRK2) are present in a subset of Parkinson's disease (PD) patients and may represent an attractive therapeutic target. Here we report a 2-anilino-4-methylamino-5-chloropyrrolopyrimidine, JH-II-127 (18), as a potent and selective inhibitor of both
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门